查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球数位病理学市场：产品（扫描仪、软件、存储系统）、类型、应用（远程医疗、培训、疾病诊断、药物发现）、用户未来预测（直到2028年）
市场调查报告书
商品编码
1295490

全球数位病理学市场：产品（扫描仪、软件、存储系统）、类型、应用（远程医疗、培训、疾病诊断、药物发现）、用户未来预测（直到2028年）

Digital Pathology Market by Product (Scanner, Software, Storage System), Type (Human, Veterinary), Application (Teleconsulation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma & Biotech, Academia, Hospitals) - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 265 Pages | 订单完成后即时交付

价格
简介目录

全球数位病理市场规模预计在预测期内将以 13.6% 的复合年增长率增长，从 2023 年的 9 亿美元增至 2028 年的 18 亿美元。我在这里。

数位病理市场的趋势主要受到数位病理在药物开发中的越来越多的使用、新兴国家对早期癌症诊断的认识不断提高以及癌症筛查的推荐等因素驱动。

另一方面，数位病理系统的高成本预计将在一定程度上抑制市场增长。

“软件行业在预测期内将以最高复合年增长率增长”

按产品来看，软件领域预计在预测期内将以最高的复合年增长率增长。 这可能是由于病理学家对集成软件的高采用率以及各种医疗机构越来越多地采用数位病理软件解决方案进行远程初步诊断。

“人类病理学领域在预测期内将以最高复合年增长率增长”

按类型划分，人类病理学领域预计到 2023 年将以最高复合年增长率增长。 其因素包括新兴国家对早期癌症诊断的认识不断增强，以及学术研究机构、大学和病理实验室之间合作关係的扩大。

“在预测期内，药物发现领域将以最高复合年增长率增长”

按应用划分，药物发现应用领域预计在 2023 年的预测期内将以最高复合年增长率增长。 关键因素包括高通量筛选和成像、临床前和临床研究数量的增加、药物发现应用领域的巨大份额和高增长率。

“在预测期内，製药和生物技术公司将占据最大份额”

从最终用户来看，製药和生物技术公司是数位病理市场最大的最终用户。 由于数位病理学在药物毒性测试中的使用越来越多，预计到 2023 年，製药和生物技术公司将占据最大的市场份额。 生物技术公司正在将数位病理学测试用于生物样本库、生物製药研究、分子分析和个性化药物开发。

“按地区划分，北美占据数位病理市场最大份额”

按地区划分，北美在 2022 年占据最大的市场份额。 预计该市场在预测期内将出现最高增长率。 北美老年人口不断增长、癌症患病率上升、优质基础设施的存在以及有利的报销等因素正在推动北美市场的增长。

内容

第 1 章简介

第 2 章研究方法

第 3 章执行摘要

第 4 章重要考虑因素

第 5 章市场概述

  • 简介
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 生态系统市场地图
  • 价格分析
  • 新的 IVD 法规对各个市场的影响
  • 技术分析
  • 数位病理学中的人工智能 (AI)
  • 波特五力分析
  • 重大会议和活动（2023-2024）
  • 关税和法规分析
  • 主要利益相关者和采购标准
  • 专利分析

第 6 章数位病理学市场：按产品

  • 简介
  • 扫描仪
    • 明场扫描仪
    • 其他扫描仪
  • 软件
    • 集成软件
    • 独立软件
  • 存储系统

第 7 章数位病理学市场：按类型

  • 简介
  • 人类病理学
  • 动物病理学

第 8 章数位病理学市场：按应用划分

  • 简介
  • 药物发现
  • 疾病诊断
  • 培训和教育

第 9 章数位病理学市场：按最终用户划分

  • 简介
  • 製药和生物技术公司
  • 医院/参考实验室
  • 学术研究所

第 10 章数位病理学市场：按地区

  • 简介
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 瑞典
    • 丹麦
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 中东和非洲

第 11 章竞争格局

  • 概述
  • 主要公司采取的策略
  • 主要公司的收入份额分析
  • 竞争基准测试
  • 公司评级象限：领先公司
  • 业务评估象限：针对小型企业/初创企业
  • 市场份额分析
  • 竞争场景

第 12 章公司简介

  • 主要公司
    • DANAHER CORPORATION
    • KONINKLIJKE PHILIPS N.V.
    • HAMAMATSU PHOTONICS K.K.
    • F. HOFFMANN-LA ROCHE LTD.
    • SECTRA AB
    • AKOYA BIOSCIENCES, INC.
    • 3DHISTECH LTD.
    • APOLLO ENTERPRISE IMAGING CORP.
    • XIFIN, INC.
    • HURON DIGITAL PATHOLOGY
    • HOLOGIC, INC.
    • CORISTA
    • INDICA LABS INC.
    • OBJECTIVE PATHOLOGY SERVICES LIMITED
    • OPTRASCAN INC.
    • GLENCOE SOFTWARE, INC.
    • AIFORIA TECHNOLOGIES OYJ
    • PAIGE AI, INC.
    • FUJIFILM HOLDINGS CORPORATION
    • PROSCIA INC.
  • 其他公司
    • PATHAI, INC.
    • KONFOONG BIOTECH INTERNATIONAL CO., LTD.
    • MIKROSCAN TECHNOLOGIES, INC.
    • MOTIC DIGITAL PATHOLOGY
    • KANTERON SYSTEMS

第 13 章附录

简介目录
Product Code: HIT 2608

The global digital pathology market is projected to reach USD 1.8 billion by 2028 from USD 0.9 billion in 2023, at a CAGR of 13.6% during the forecast period. Growth in the digital pathology market is mainly driven by factors such as the growing applications of digital pathology in drug development , growing awareness of early cancer diagnosis in emerging economies, and recommendations for cancer screening.

On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent.

Software segment is projected to grow at the highest CAGR during the forecast period By product, the global digital pathology market is segmented into scanners, software, and storage systems. The software segment is projected to grow at the highest CAGR during the forecast period.This can be attributed to the high adoption of integrated software by pathologists, and increased adoption of digital pathology software solutions in various healthcare facilities for remote primary diagnosis.

Human pathology segment is projected to grow at the highest CAGR during the forecast period By type, the digital pathology market is segmented into human pathology and veterinary pathology. In 2023, the human pathology segment is projected to grow at the highest CAGR due to the growing awareness of early cancer diagnosis in emerging economies, and growing collaborations among academic research institutes, universities, and pathology laboratories.

Drug discovery segment is projected to grow at the highest CAGR during the forecast period

By application, the digital pathology market is segmented into drug discovery, disease diagnosis, and training & education. In 2023, drug discovery application segment is projected to grow at the highest CAGR during the forecast period. The growth in high throughput screening and imaging, and the rising number of preclinical & clinical studies are the major factors responsible for the large share and high growth rate of the drug discovery application segment.

Pharmaceutical & biotechnology companies end user segment is projected to account for the largest share of the digital pathology market By end user, the digital pathology market is broadly segmented into pharmaceutical & biotechnology companies, hospitals & reference laboratories, and academic & research institutes. Pharmaceutical & biotechnology companies are the largest end users of the digital pathology market. In 2023, the pharmaceutical & biotechnology companies segment is projected to account for the largest share of the digital pathology market due to growing use of digital pathology for drug toxicology testing. Biotechnology companies use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

By region, North America is projected to account for the largest share of the digital pathology market

By region,North America accounted for the largest share of the digital pathology market in 2022. During the forecast period this market is expected to grow at the highest rate. Factors such as the growing geriatric population, rising prevalence of cancer, the presence of high-quality infrastructure, and the favorable reimbursement in the region are driving the growth of the market in North America.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 - 35%, Tier 2 - 45%, and Tier 3 - 20% * By Designation: C-level - 35%, Director-level - 25%, and Others - 40% * By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%,Middle East & Africa-5%

Some of the prominent players operating in the digital pathology market include Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), , Objective Pathology Services Limited (Canada), Sectra AB (Sweden), OptraSCAN (US), Akoya Biosciences, Inc. (US), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), and Kanteron Systems (Spain).

Research Coverage

This report studies the digital pathology market based on type, application, product, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

This report provides insights into the following pointers:

Analysis of key drivers (increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, growing applications of digital pathology in drug development and companion diagnostics, growing awareness of early cancer diagnosis in emerging economies, and recommendations for cancer screening),opportunities (introduction of affordable scanners for private pathology practices, growing demand for personalized medicine, and high growth opportunities in emerging economies) and challenges (shortage of trained pathologists) influencing the growth of digital pathology market.

Market Penetration: Comprehensive information on product portfolios offered by the top players in the global digital pathology market . The report analyzes this market by product, type, application, end user, and region

Product Development/Innovation: Detailed insights on upcoming trends and product launches in the global digital pathology market

Market Development: Comprehensive information on the lucrative emerging markets by product, type, application, end user, and region

Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global digital pathology market

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global digital pathology market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 DIGITAL PATHOLOGY MARKET
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 STUDY LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 ECONOMIC RECESSION IMPACT ON DIGITAL PATHOLOGY MARKET

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
  • 2.2 RESEARCH DESIGN
    • FIGURE 2 RESEARCH DESIGN
    • 2.2.1 SECONDARY RESEARCH
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY RESEARCH
    • FIGURE 3 PRIMARY SOURCES
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Insights from primary experts
      • 2.2.2.3 Breakdown of primaries
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 6 DIGITAL PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION OF DANAHER CORPORATION
    • FIGURE 7 BOTTOM-UP APPROACH
    • FIGURE 8 CAGR PROJECTIONS
    • FIGURE 9 IMPACT ON MARKET GROWTH AND CAGR: ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023-2028)
  • 2.4 DATA TRIANGULATION APPROACH
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT: DIGITAL PATHOLOGY MARKET
  • 2.8 MARKET LIMITATIONS
    • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 11 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 DIGITAL PATHOLOGY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 DIGITAL PATHOLOGY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF DIGITAL PATHOLOGY MARKET

4 PREMIUM INSIGHTS

  • 4.1 DIGITAL PATHOLOGY MARKET OVERVIEW
    • FIGURE 16 RISING PREVALENCE OF CANCER TO DRIVE MARKET
  • 4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER & COUNTRY (2022)
    • FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN DIGITAL PATHOLOGY MARKET IN 2022
  • 4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 UK TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • 4.4 REGIONAL MIX: DIGITAL PATHOLOGY MARKET (2023-2028)
    • FIGURE 19 NORTH AMERICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023-2028)
  • 4.5 DIGITAL PATHOLOGY MARKET: DEVELOPING VS. DEVELOPED MARKETS
    • FIGURE 20 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing adoption of digital pathology to enhance lab efficiency
      • 5.2.1.2 Rising incidence of cancer
    • FIGURE 22 GLOBAL CANCER INCIDENCE, 2008-2030
    • TABLE 2 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
      • 5.2.1.3 Growing applications of digital pathology in drug development and companion diagnostics
      • 5.2.1.4 Growing awareness of early cancer diagnosis in emerging economies
      • 5.2.1.5 Recommendations for cancer screening
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of digital pathology systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Introduction of affordable scanners for private pathology practices
      • 5.2.3.2 Growing demand for personalized medicine
    • TABLE 3 US: GROWTH IN NUMBER OF PERSONALIZED MEDICINES, 2008-2020
    • FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015-2021
      • 5.2.3.3 High growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of trained pathologists
    • TABLE 4 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020
  • 5.3 ECOSYSTEM MARKET MAP
    • FIGURE 24 DIGITAL PATHOLOGY MARKET: ECOSYSTEM MARKET MAP
  • 5.4 PRICING ANALYSIS
    • FIGURE 25 AVERAGE SELLING PRICE TREND OF SCANNERS, BY REGION, 2018-2025
  • 5.5 IMPACT OF NEW IVD REGULATION ON DIFFERENT MARKETS
    • FIGURE 26 TIMELINE AND TRANSITION TO NEW MDR AND IVDR
    • 5.5.1 IMPACT ON CLINICAL LAB SERVICES
    • 5.5.2 IMPACT ON IVD
    • 5.5.3 IMPACT ON DIGITAL PATHOLOGY
  • 5.6 TECHNOLOGY ANALYSIS
  • 5.7 ARTIFICIAL INTELLIGENCE (AI) IN DIGITAL PATHOLOGY
    • 5.7.1 LABEL-FREE IMAGING IN DIGITAL PATHOLOGY
    • 5.7.2 COMPUTATIONAL IMAGE ANALYSIS IN DIGITAL PATHOLOGY
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 KEY CONFERENCES & EVENTS, 2023-2024
    • TABLE 5 DIGITAL PATHOLOGY MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.10 TARIFF AND REGULATORY ANALYSIS
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 REGULATORY ANALYSIS
      • 5.10.2.1 North America
        • 5.10.2.1.1 US
    • TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 8 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
        • 5.10.2.1.2 Canada
    • TABLE 9 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
      • 5.10.2.2 Europe
    • TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES
    • FIGURE 27 EUROPE: IVDR TIMELINE
      • 5.10.2.3 Asia Pacific
        • 5.10.2.3.1 Japan
    • TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
        • 5.10.2.3.2 China
    • TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
        • 5.10.2.3.3 India
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DIGITAL PATHOLOGY PRODUCTS
    • TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DIGITAL PATHOLOGY PRODUCTS (%)
    • 5.11.2 BUYING CRITERIA
    • FIGURE 29 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
    • TABLE 14 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
  • 5.12 PATENT ANALYSIS
    • 5.12.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 30 TOP PATENT OWNERS AND APPLICANTS: DIGITAL PATHOLOGY MARKET (JANUARY 2011-FEBRUARY 2023)
    • FIGURE 31 TOP APPLICANT JURISDICTIONS FOR DIGITAL PATHOLOGY MARKET (JANUARY 2011-FEBRUARY 2023)
    • 5.12.2 PATENT PUBLICATION TRENDS FOR DIGITAL PATHOLOGY MARKET
    • FIGURE 32 PATENT ANALYSIS: DIGITAL PATHOLOGY MARKET (JANUARY 2011-FEBRUARY 2023)
    • TABLE 15 LIST OF PATENTS/PATENT APPLICATIONS IN DIGITAL PATHOLOGY MARKET, 2020-2023

6 DIGITAL PATHOLOGY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 16 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 SCANNERS
    • TABLE 17 SCANNING MAGNIFICATION AND APPLICATIONS
    • TABLE 18 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS
    • TABLE 19 DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 20 DIGITAL PATHOLOGY SCANNERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.1 BRIGHTFIELD SCANNERS
      • 6.2.1.1 Ideal solutions for small laboratories
    • TABLE 21 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS
    • TABLE 22 BRIGHTFIELD SCANNERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.2 OTHER SCANNERS
    • TABLE 23 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS
    • TABLE 24 OTHER SCANNERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 SOFTWARE
    • TABLE 25 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS
    • TABLE 26 DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 27 DIGITAL PATHOLOGY SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.1 INTEGRATED SOFTWARE
      • 6.3.1.1 Includes various modules for different digital pathology applications
    • TABLE 28 INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS
    • TABLE 29 INTEGRATED SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.2 STANDALONE SOFTWARE
    • TABLE 30 STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 31 STANDALONE SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.1 Information management software
        • 6.3.2.1.1 Enables comprehensive integration with information systems of any institute
    • TABLE 32 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS
    • TABLE 33 INFORMATION MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.2 Image analysis software
        • 6.3.2.2.1 Provides easy-to-use solutions for quantitative evaluation of brightfield slides
    • TABLE 34 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS
    • TABLE 35 IMAGE ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 STORAGE SYSTEMS
    • 6.4.1 NEED FOR SAFE AND RELIABLE STORAGE OF HIGH-QUALITY IMAGES TO DRIVE MARKET
    • TABLE 36 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS
    • TABLE 37 STORAGE SYSTEMS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 DIGITAL PATHOLOGY MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 38 DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 7.2 HUMAN PATHOLOGY
    • 7.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO DRIVE MARKET
    • TABLE 39 HUMAN DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 VETERINARY PATHOLOGY
    • 7.3.1 REDUCTION IN TURNAROUND TIME FOR ANIMAL DISEASE DIAGNOSIS TO DRIVE MARKET
    • TABLE 40 VETERINARY DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 DIGITAL PATHOLOGY MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 41 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 42 PRODUCT CROSS-MAPPING FOR DIFFERENT APPLICATIONS
  • 8.2 DRUG DISCOVERY
    • 8.2.1 LARGEST AND FASTEST-GROWING SEGMENT OF MARKET
    • TABLE 43 APPLICATIONS OF DIGITAL PATHOLOGY IN DRUG DISCOVERY
    • TABLE 44 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 DISEASE DIAGNOSIS
    • 8.3.1 USE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIGITAL PATHOLOGY SOLUTIONS TO PROPEL MARKET
    • TABLE 45 DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 TRAINING & EDUCATION
    • 8.4.1 DIGITAL PATHOLOGY CAN IMPROVE EDUCATION & TRAINING PROVIDED TO PATHOLOGISTS IN ACADEMIC INSTITUTES
    • TABLE 46 DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2021-2028 (USD MILLION)

9 DIGITAL PATHOLOGY MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 47 DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 48 PRODUCT CROSS-MAPPING FOR DIFFERENT END USERS
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 RISING USE OF DIGITAL PATHOLOGY IN DRUG DEVELOPMENT TO DRIVE MARKET
    • TABLE 49 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 HOSPITALS & REFERENCE LABORATORIES
    • 9.3.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
    • TABLE 50 HOSPITAL DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS
    • TABLE 51 DIGITAL PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 INCREASING INVESTMENTS FOR RESEARCH IN DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH
    • TABLE 52 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)

10 DIGITAL PATHOLOGY MARKET, BY REGION

  • 10.1 INTRODUCTION
    • FIGURE 33 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • TABLE 53 DIGITAL PATHOLOGY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • 10.2.1 IMPACT OF RECESSION ON NORTH AMERICAN DIGITAL PATHOLOGY MARKET
    • FIGURE 34 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT
    • TABLE 54 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 56 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 58 NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 59 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 Rapidly increasing geriatric population and growing prevalence of chronic diseases to drive market
    • TABLE 62 US: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 63 US: KEY MACROINDICATORS
    • TABLE 64 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 65 US: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 66 US: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 67 US: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 68 US: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 69 US: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 70 US: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing government initiatives for cancer awareness to drive market growth
    • TABLE 71 CANADA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 72 CANADA: DIGITAL PATHOLOGY INITIATIVES AND FUNDING
    • TABLE 73 CANADA: KEY MACROINDICATORS
    • TABLE 74 CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 75 CANADA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 76 CANADA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 77 CANADA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 78 CANADA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 79 CANADA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 80 CANADA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 IMPACT OF RECESSION ON EUROPEAN DIGITAL PATHOLOGY MARKET
    • TABLE 81 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 83 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 84 EUROPE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 86 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 88 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Rising government funding and initiatives to drive market
    • TABLE 89 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 90 UK: KEY MACROINDICATORS
    • TABLE 91 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 92 UK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 UK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 94 UK: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 95 UK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 96 UK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 97 UK: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 GERMANY
      • 10.3.3.1 High healthcare expenditure and supportive research initiatives to drive market
    • TABLE 98 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 99 GERMANY: KEY MACROINDICATORS
    • TABLE 100 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 101 GERMANY: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 GERMANY: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 103 GERMANY: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 104 GERMANY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 GERMANY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 106 GERMANY: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 SWEDEN
      • 10.3.4.1 Increasing prevalence of chronic diseases to support market growth
    • TABLE 107 SWEDEN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 108 SWEDEN: KEY MACROINDICATORS
    • TABLE 109 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 110 SWEDEN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 111 SWEDEN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 112 SWEDEN: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 113 SWEDEN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 SWEDEN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 115 SWEDEN: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 DENMARK
      • 10.3.5.1 Increasing deployment of digital pathology solutions to support market growth
    • TABLE 116 DENMARK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 117 DENMARK: KEY MACROINDICATORS
    • TABLE 118 DENMARK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 119 DENMARK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 DENMARK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 121 DENMARK: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 DENMARK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 123 DENMARK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 124 DENMARK: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 FRANCE
      • 10.3.6.1 Increasing government funding and favorable insurance system to drive adoption
    • TABLE 125 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 126 FRANCE: KEY MACROINDICATORS
    • TABLE 127 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 128 FRANCE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 FRANCE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 FRANCE: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 131 FRANCE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 132 FRANCE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 133 FRANCE: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 134 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 135 REST OF EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 REST OF EUROPE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 REST OF EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 138 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 139 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 140 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • 10.4.1 IMPACT OF RECESSION ON ASIA PACIFIC DIGITAL PATHOLOGY MARKET
    • FIGURE 35 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET SNAPSHOT
    • TABLE 141 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 143 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 ASIA PACIFIC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 145 ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 147 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 148 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Rising geriatric population to drive demand for digital pathology products
    • TABLE 149 CHINA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 150 CHINA: KEY MACROINDICATORS
    • TABLE 151 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 152 CHINA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 153 CHINA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 154 CHINA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 CHINA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 156 CHINA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 157 CHINA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Advanced healthcare infrastructure to support market growth
    • TABLE 158 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 159 JAPAN: KEY MACROINDICATORS
    • TABLE 160 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 161 JAPAN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 162 JAPAN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 163 JAPAN: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 164 JAPAN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 JAPAN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 166 JAPAN: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Increasing awareness regarding benefits of digital pathology solutions to drive market
    • TABLE 167 INDIA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 168 INDIA: KEY MACROINDICATORS
    • TABLE 169 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 170 INDIA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 INDIA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 INDIA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 173 INDIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 174 INDIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 175 INDIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 176 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 177 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 178 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 179 REST OF ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 180 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 181 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 182 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 IMPACT OF RECESSION ON LATIN AMERICAN DIGITAL PATHOLOGY MARKET
    • TABLE 183 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 184 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 185 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 LATIN AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 187 LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 188 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 189 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 190 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.2 BRAZIL
      • 10.5.2.1 Rising initiatives to drive adoption of digital pathology solutions
    • TABLE 191 BRAZIL: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 192 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 193 BRAZIL: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 194 BRAZIL: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 195 BRAZIL: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 196 BRAZIL: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 197 BRAZIL: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 198 BRAZIL: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.3 MEXICO
      • 10.5.3.1 Rising burden of cancer to drive uptake of digital pathology solutions
    • TABLE 199 MEXICO: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 200 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 201 MEXICO: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 202 MEXICO: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 203 MEXICO: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 204 MEXICO: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 205 MEXICO: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 206 MEXICO: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.4 REST OF LATIN AMERICA
    • TABLE 207 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 208 REST OF LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 209 REST OF LATIN AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 210 REST OF LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 211 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 212 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 213 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 INFRASTRUCTURAL DEVELOPMENTS TO SUPPORT MARKET GROWTH
    • 10.6.2 IMPACT OF RECESSION ON MIDDLE EAST & AFRICAN DIGITAL PATHOLOGY MARKET
    • TABLE 214 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 215 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 216 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 217 MIDDLE EAST AND AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 218 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 219 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 220 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 36 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET
  • 11.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
    • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL PATHOLOGY MARKET
  • 11.4 COMPETITIVE BENCHMARKING
    • TABLE 221 FOOTPRINT ANALYSIS OF COMPANIES IN DIGITAL PATHOLOGY MARKET
    • TABLE 222 PRODUCT FOOTPRINT ANALYSIS OF COMPANIES
    • TABLE 223 APPLICATION FOOTPRINT ANALYSIS OF COMPANIES
    • TABLE 224 END-USER FOOTPRINT ANALYSIS OF COMPANIES
    • TABLE 225 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES
  • 11.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 38 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS (2022)
  • 11.6 COMPANY EVALUATION QUADRANT FOR SMES/STARTUPS
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 DYNAMIC COMPANIES
    • 11.6.3 STARTING BLOCKS
    • 11.6.4 RESPONSIVE COMPANIES
    • FIGURE 39 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION QUADRANT FOR SMES/ STARTUPS (2022)
  • 11.7 MARKET SHARE ANALYSIS
    • FIGURE 40 DIGITAL PATHOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
    • TABLE 226 DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 227 KEY PRODUCT LAUNCHES AND APPROVALS
    • 11.8.2 DEALS
    • TABLE 228 KEY DEALS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 DANAHER CORPORATION
    • TABLE 229 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.2 KONINKLIJKE PHILIPS N.V.
    • TABLE 230 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
    • FIGURE 42 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
    • 12.1.3 HAMAMATSU PHOTONICS K.K.
    • TABLE 231 HAMAMATSU PHOTONICS K.K.: BUSINESS OVERVIEW
    • FIGURE 43 HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2022)
    • 12.1.4 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 232 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • 12.1.5 SECTRA AB
    • TABLE 233 SECTRA AB: BUSINESS OVERVIEW
    • FIGURE 45 SECTRA AB: COMPANY SNAPSHOT (2021)
    • 12.1.6 AKOYA BIOSCIENCES, INC.
    • TABLE 234 AKOYA BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • FIGURE 46 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.7 3DHISTECH LTD.
    • TABLE 235 3DHISTECH LTD.: BUSINESS OVERVIEW
    • 12.1.8 APOLLO ENTERPRISE IMAGING CORP.
    • TABLE 236 APOLLO ENTERPRISE IMAGING CORP.: BUSINESS OVERVIEW
    • 12.1.9 XIFIN, INC.
    • TABLE 237 XIFIN, INC.: BUSINESS OVERVIEW
    • 12.1.10 HURON DIGITAL PATHOLOGY
    • TABLE 238 HURON DIGITAL PATHOLOGY: BUSINESS OVERVIEW
    • 12.1.11 HOLOGIC, INC.
    • TABLE 239 HOLOGIC, INC.: BUSINESS OVERVIEW
    • FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.12 CORISTA
    • TABLE 240 CORISTA: BUSINESS OVERVIEW
    • 12.1.13 INDICA LABS INC.
    • TABLE 241 INDICA LABS INC.: BUSINESS OVERVIEW
    • 12.1.14 OBJECTIVE PATHOLOGY SERVICES LIMITED
    • TABLE 242 OBJECTIVE PATHOLOGY SERVICES LIMITED: BUSINESS OVERVIEW
    • 12.1.15 OPTRASCAN INC.
    • TABLE 243 OPTRASCAN INC.: BUSINESS OVERVIEW
    • 12.1.16 GLENCOE SOFTWARE, INC.
    • TABLE 244 GLENCOE SOFTWARE, INC.: BUSINESS OVERVIEW
    • 12.1.17 AIFORIA TECHNOLOGIES OYJ
    • TABLE 245 AIFORIA TECHNOLOGIES OYJ: BUSINESS OVERVIEW
    • 12.1.18 PAIGE AI, INC.
    • TABLE 246 PAIGE AI, INC.: BUSINESS OVERVIEW
    • 12.1.19 FUJIFILM HOLDINGS CORPORATION
    • TABLE 247 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 48 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.20 PROSCIA INC.
    • TABLE 248 PROSCIA, INC.: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 PATHAI, INC.
    • 12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD.
    • 12.2.3 MIKROSCAN TECHNOLOGIES, INC.
    • 12.2.4 MOTIC DIGITAL PATHOLOGY
    • 12.2.5 KANTERON SYSTEMS
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS